Monthly information regarding the total number of voting rights and
See original here:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020
Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season
Read more:
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
The rest is here:
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2)...
HOUSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs, is proud to announce Global Smart Leaders Magazine has named them the #2 Most Innovative Company of 2020. The detailed profile interview can be found here: https://globalsmartleaders.com/fibrogenesis-treatingcovid-19-and-other-chronic/
BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Matt David, M.D., Executive Vice President and Chief Financial Officer of CorMedix, will present a company overview and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13 – 15, 2020. The Company’s presentation will be available on demand for BIO Investor Forum attendees.
Original post:
CorMedix to Participate in BIO Investor Forum Digital
Steven H. Rouhandeh Appointed as Chairman of the Board of Directors
See the original post:
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
- Application Assigned a PDUFA Date of May 27, 2021
See the rest here:
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection
TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that its abstract submitted to the American Society of Hematology (ASH) annual meeting 2020, reporting on positive results achieved from a diagnostic/prognostic smoldering multiple myeloma (SMM) ‘proof of concept’ study, was selected for online publication. The abstract will be included in the November supplemental issue of the scientific journal Blood, published by ASH.
Go here to see the original:
Telo Genomics Announces that Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within ASH 2020 Proceedings
BALA CYNWYD, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB). Larimar’s SAB is comprised of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease.
Continued here:
Larimar Therapeutics Announces Formation of Scientific Advisory Board
Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first patient has been randomized in Part B of its “TRAVERS” Phase 2 trial of AM-125 (intranasal betahistine) in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September 2020, the completion of enrollment into the oral treatment group, and the receipt of regulatory clearance for Part B in the first three of the participating study countries.
See the original post here:
Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo